Insider · CIK 0001886325
Gerhard Koenig
director
Files at VIGL (Vigil Neuroscience, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 5, 2025 | VIGL Vigil Neuroscience, Inc. | DDisposition to issuer Common Stock | -5,000 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | VIGL Vigil Neuroscience, Inc. | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -18,029 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | VIGL Vigil Neuroscience, Inc. | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -6,954 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | VIGL Vigil Neuroscience, Inc. | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -36,690 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | VIGL Vigil Neuroscience, Inc. | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -18,068 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | VIGL Vigil Neuroscience, Inc. | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -13,928 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | VIGL Vigil Neuroscience, Inc. | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -4,351 | - | - | 0 | Aug 5, 2025 |
| Aug 5, 2025 | VIGL Vigil Neuroscience, Inc. | DDisposition to issuer Stock Option Award (Right to Buy)derivative | -12,155 | - | - | 0 | Aug 5, 2025 |
| May 22, 2025 | VIGL Vigil Neuroscience, Inc. | AGrant or award Common Stock | +5,000 | $0.00 | $0 | 5,000 | May 23, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.